StockData
Regencell Bioscience Holdings Ltd logo

Regencell Bioscience Holdings Ltd (RGC) stock

RGCNasdaqMedicinal Chemicals & Botanical Products
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 7, 2026Score 5/30
$4.69+0.14 (+3.08%)

Close on Nov 18, 2026Market cap $2.33BP/E –Yield –

Regencell Bioscience operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

For fiscal 2026 it was -$7.70M. The highest annual figure on record is -$390.99K in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$7.70M–
FY2025Jun 30, 2025-$3.11M–
FY2024Jun 30, 2024-$4.00M–
FY2023Jun 30, 2023-$4.96M–
FY2022Jun 30, 2022-$5.27M–
FY2021Jun 30, 2021-$767.31K–
FY2020Jun 30, 2020-$726.57K–
FY2019Jun 30, 2019-$390.99K–

More Regencell Bioscience figures

See a number that looks wrong?